NAUT
Nautilus Biotechnology, Inc.
$2.17
-3.56%
$275.8M
No data for this timeframe.
Vol
Market Cap$275.8M
Cap SizeMicro Cap
Inst. Holders32 funds
Inst. Value$20.4M
Inst. Activity5 buys / 2 sells
Insider Activity0B / 1S
Insider Net $-$10.8M
Reddit Sentiment33° Cool
SEC Reports3
Press Releases1
Recent Activity
Jun 2, 2026
Insider
AH Equity Partners Bio II, L.L.C. sold 4,615,974 shares
10%+ Owner @ $2.35 ($10.8M)
Apr 28, 2026
SEC
Nautilus Biotechnology reported Q1 2026 EPS of -$0.12, beating consensus of -$0.14 by 17.2%, with revenue still at $0 as
PRESS-RELEASE — Impact 4/10
Apr 28, 2026
earnings
Nautilus Biotechnology Reports First Quarter 2026 Financial Results
<p align="justify">SEATTLE, April 28, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDA
Apr 28, 2026
SEC
Nautilus Biotechnology reported Q1 2026 results: net loss of $14.7M improved from $16.6M a year ago, with operating expe
8-K — Impact 4/10
Mar 18, 2026
Press
Nautilus Biotechnology announced that Baylor College of Medicine has joined its Iterative Mapping Early Access Program,
Impact 6/10
Mar 2, 2026
Insider
Weld Gwen E was granted 160,000 shares
Chief People Officer
Mar 2, 2026
Insider
Mallick Parag was granted 280,000 shares
Chief Scientist
Feb 26, 2026
SEC
Nautilus Biotechnology reported reduced operating expenses and net losses for Q4 and full-year 2025, with $156.1 million
8-K — Impact 4/10
Price Targets
Historical data — last covering-analyst action Feb 2026. No current recommendation available.
$4.00 (Feb 2026)
Current $2.17
Low $4.00
Median $4.00
High $4.00
1 analysts
$4.00
$4.00
Analyst Ratings
3Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Feb 27, 2026 | Guggenheim | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.14 | $-0.14 — $-0.14 | -17% YoY | 1 |
| Next Q | $-0.15 ▼ -7.1% | $-0.15 — $-0.15 | -36% YoY | 1 |
| Current FY | $-0.52 ▲ +6.4% | $-0.52 — $-0.51 | -10% YoY | 2 |
| Next FY | $-0.52 ▲ +5.5% | $-0.61 — $-0.43 | -1% YoY | 2 |
Latest Reports
NEUTRAL
PRESS-RELEASE
4/10
Nautilus Biotechnology reported Q1 2026 EPS of -$0.12, beating consensus of -$0.14 by 17.2%, with revenue still at $0 as
Apr 28, 2026
NEUTRAL
8-K
4/10
Nautilus Biotechnology reported Q1 2026 results: net loss of $14.7M improved from $16.6M a year ago, with operating expe
Apr 28, 2026
MIXED
Press
6/10
Nautilus Biotechnology announced that Baylor College of Medicine has joined its Iterative Mapping Early Access Program,
Mar 18, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| ROYAL BANK OF CANADA | — | TRIM |
| VANGUARD CAPITAL MANAGEMENT LLC | $9.9M | — |
| GOLDMAN SACHS GROUP INC | $1.5M | — |
| DIMENSIONAL FUND ADVISORS LP | $1.3M | TRIM |
| MARSHALL WACE, LLP | $1.2M | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 2, 2026 | AH Equity | SELL | $10.8M |
| Mar 2, 2026 | Weld Gwen | A | $0.00 |
| Mar 2, 2026 | Mallick Parag | A | $0.00 |
| Mar 2, 2026 | Sankar Subramanian | A | $0.00 |
| Mar 2, 2026 | Suzuki Kentaro | A | $0.00 |
Reddit Sentiment
33°
Cool
Bearish
Neutral
Bullish
32 institutional holders with $20.4M total value (5,330,016 shares) as of 2026-Q1. Top holders: ROYAL, VANGUARD, GOLDMAN. Net buying activity: 5 institutions added/increased vs 2 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | ROYAL BANK OF CANADA | 91 | $0.00 | 0.0% | TRIM -59.2% |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 2,545,597 | $9.9M | 48.4% | — |
| 3 | GOLDMAN SACHS GROUP INC | 390,768 | $1.5M | 7.4% | — |
| 4 | DIMENSIONAL FUND ADVISORS LP | 329,123 | $1.3M | 6.2% | TRIM -33.8% |
| 5 | MARSHALL WACE, LLP | 319,882 | $1.2M | 6.1% | DOUBLED +173.3% |
| 6 | VANGUARD FIDUCIARY TRUST CO | 305,526 | $1.2M | 5.8% | — |
| 7 | RENAISSANCE TECHNOLOGIES LLC | 265,700 | $1.0M | 5.0% | TRIM -74.2% |
| 8 | STATE STREET CORP | 216,270 | $839.1K | 4.1% | NEAR_EXIT -80.1% |
| 9 | BlackRock, Inc. | 187,671 | $728.2K | 3.6% | TRIM -68.0% |
| 10 | Point72 Asset Management, L.P. | 83,043 | $322.2K | 1.6% | ADD +36.5% |
| 11 | BARCLAYS PLC | 73,325 | $284.5K | 1.4% | TRIM -42.5% |
| 12 | BANK OF AMERICA CORP /DE/ | 63,147 | $245.0K | 1.2% | DOUBLED +213.1% |
| 13 | Brevan Howard Capital Management LP | 60,501 | $234.7K | 1.1% | — |
| 14 | MORGAN STANLEY | 49,503 | $192.1K | 0.9% | ADD +28.3% |
| 15 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 49,200 | $190.9K | 0.9% | — |
| 16 | HSBC HOLDINGS PLC | 49,449 | $189.9K | 0.9% | DOUBLED +182.5% |
| 17 | FAYEZ SAROFIM & CO | 45,000 | $174.6K | 0.9% | — |
| 18 | POLEN CAPITAL MANAGEMENT LLC | 40,345 | $156.5K | 0.8% | — |
| 19 | SEI INVESTMENTS CO | 38,643 | $149.9K | 0.7% | — |
| 20 | CAPTRUST FINANCIAL ADVISORS | 34,003 | $131.9K | 0.6% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MARSHALL WACE, LLP | DOUBLED | 117,059 | 319,882 | +173.3% | $1.2M | 2026-Q1 |
| Point72 Asset Management, L.P. | ADD | 60,833 | 83,043 | +36.5% | $322.2K | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 20,167 | 63,147 | +213.1% | $245.0K | 2026-Q1 |
| MORGAN STANLEY | ADD | 38,584 | 49,503 | +28.3% | $192.1K | 2026-Q1 |
| Hudson Bay Capital Management LP | ADD | 19,062 | 29,594 | +55.3% | $114.8K | 2026-Q1 |
| OMERS ADMINISTRATION Corp | NEAR_EXIT | 104,785 | 24,500 | -76.6% | $95.1K | 2026-Q1 |
| CWM, LLC | TRIM | 55 | 29 | -47.3% | $113.00 | 2026-Q1 |
| CWM, LLC | TRIM | 182 | 55 | -69.8% | — | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 1,007,662 | 259,900 | -74.2% | $506.8K | 2025-Q4 |
| Corient Private Wealth LLC | TRIM | 319,140 | 114,788 | -64.0% | $223.8K | 2025-Q4 |
| MORGAN STANLEY | ADD | 25,728 | 38,584 | +50.0% | $75.2K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 813 | 20,167 | +2380.6% | $39.3K | 2025-Q4 |
| FMR LLC | TRIM | 8,660 | 3,486 | -59.7% | $6.8K | 2025-Q4 |
| CWM, LLC | NEAR_EXIT | 3,000 | 182 | -93.9% | — | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 619,906 | 1,007,662 | +62.6% | $851.4K | 2025-Q3 |
| DIMENSIONAL FUND ADVISORS LP | TRIM | 550,740 | 364,675 | -33.8% | $307.8K | 2025-Q3 |
| Corient Private Wealth LLC | TRIM | 435,350 | 319,140 | -26.7% | $269.6K | 2025-Q3 |
| CITADEL ADVISORS LLC | ADD | 178,155 | 254,161 | +42.7% | $214.7K | 2025-Q3 |
| BlackRock, Inc. | TRIM | 628,901 | 201,444 | -68.0% | $170.2K | 2025-Q3 |
| MORGAN STANLEY | TRIM | 54,577 | 25,728 | -52.9% | $21.7K | 2025-Q3 |
| FMR LLC | TRIM | 24,498 | 8,660 | -64.7% | $7.3K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 8,363 | 813 | -90.3% | $686.00 | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | TRIM | 1,443 | 560 | -61.2% | $473.00 | 2025-Q3 |
| UBS Group AG | NEAR_EXIT | 16,320 | 470 | -97.1% | $397.00 | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 300,456 | 619,906 | +106.3% | $449.4K | 2025-Q2 |
7 unique insiders with 7 transactions. Net insider value: -$10.8M ($0.00 bought, $10.8M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 2, 2026 | AH Equity Partners Bio II, L.L.C. | 10%+ Owner | SELL | 4,615,974 | $2.35 | $10.8M |
| Mar 2, 2026 | Weld Gwen E | Chief People Officer | AWARD | 160,000 | — | — |
| Mar 2, 2026 | Mallick Parag | Chief Scientist | AWARD | 280,000 | — | — |
| Mar 2, 2026 | Sankar Subramanian | Senior VP, Product Development | AWARD | 160,000 | — | — |
| Mar 2, 2026 | Suzuki Kentaro | Chief Marketing Officer | AWARD | 160,000 | — | — |
| Mar 2, 2026 | Patel Sujal M | CEO, President, and Secretary | AWARD | 650,000 | — | — |
| Mar 2, 2026 | Murphy Matthew B. | General Counsel | AWARD | 160,000 | — | — |
3 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 3 neutral. Avg impact: 4.0/10.
NEUTRAL
PRESS-RELEASE
4/10
Nautilus Biotechnology reported Q1 2026 EPS of -$0.12, beating consensus of -$0.14 by 17.2%, with re
Apr 28, 2026
NEUTRAL
8-K
4/10
Nautilus Biotechnology reported Q1 2026 results: net loss of $14.7M improved from $16.6M a year ago,
Apr 28, 2026
NEUTRAL
8-K
4/10
Nautilus Biotechnology reported reduced operating expenses and net losses for Q4 and full-year 2025,
Feb 26, 2026
Historical analyst distribution (last covering-analyst action Feb 2026): 88% buy across 8 analysts — 3 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Feb 2026. No current recommendation available.
$4.00 mean target (Feb 2026)
$4.00 Low
$4.00 High
| Metric | Value |
|---|---|
| Current Price | $2.17 |
| Target Low | $4.00 |
| Target Mean | $4.00 |
| Target Median | $4.00 |
| Target High | $4.00 |
| # Analysts | 1 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.14 | $-0.14 | $-0.14 | -16.7% | +0.0% | — | $0.0B | 0.0% | 1 |
| Next Q 2026-09-30 |
$-0.15 | $-0.15 | $-0.15 | -36.4% | -7.1% | 0↑ 1↓ | $0.0B | 0.0% | 1 |
| Current FY 2026-12-31 |
$-0.52 | $-0.52 | $-0.51 | -9.6% | +6.4% | 2↑ 0↓ | $0.0B | 0.0% | 2 |
| Next FY 2027-12-31 |
$-0.52 | $-0.61 | $-0.43 | -1.0% | +5.5% | 2↑ 0↓ | $0.0B | 992.9% | 2 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.140 | |
| 7d ago | $-0.145 | +0.005 |
| 30d ago | $-0.140 | |
| 60d ago | $-0.140 | |
| 90d ago | $-0.150 | +0.010 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Feb 27, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 4 | 1 | 0 | 0 | 88% | |
| May 1, 2026 | 3 | 4 | 1 | 0 | 0 | 88% | |
| Apr 1, 2026 | 3 | 4 | 1 | 0 | 0 | 88% | |
| Mar 1, 2026 | 3 | 4 | 1 | 0 | 0 | 88% | |
| Feb 1, 2026 | 3 | 4 | 1 | 0 | 0 | 88% | |
| Jan 1, 2026 | 3 | 4 | 1 | 0 | 0 | 88% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
33°
Cool
Bearish
Neutral
Bullish
2 mentions
0 bullish
2 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Apr 13, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Apr 13, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
Recent Reddit Threads
Apr 28, 2026
earnings
Nautilus Biotechnology Reports First Quarter 2026 Financial Results
<p align="justify">SEATTLE, April 28, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule p
Apr 28, 2026
earnings_calendar
NAUT Q1 2026 Earnings Scheduled — 2026-04-28
Mar 25, 2026
short_volume
Short Volume: NAUT — 61.4% short (0.3M / 0.5M)
Short: 318,091 | Exempt: 7,676 | TRF Vol: 517,815 | Short Ratio: 61.4% | Off-exchange volume (dark pool + OTC)
Mar 24, 2026
short_volume
Short Volume: NAUT — 68.4% short (0.4M / 0.6M)
Short: 427,774 | Exempt: 49,252 | TRF Vol: 625,495 | Short Ratio: 68.4% | Off-exchange volume (dark pool + OTC)
Mar 23, 2026
short_volume
Short Volume: NAUT — 64.9% short (0.4M / 0.6M)
Short: 376,823 | Exempt: 8,740 | TRF Vol: 580,290 | Short Ratio: 64.9% | Off-exchange volume (dark pool + OTC)
Mar 18, 2026
fda
Nautilus Biotechnology Announces Baylor College of Medicine as First Early Access Program Customer for Voyager Platform
<p align="center"><em>• Baylor selects the Nautilus Voyager™ Platform, now available through Early Access Program, for development of a first-in-class
Feb 26, 2026
earnings_calendar
NAUT Q4 2025 Earnings Before Market Open — 2026-02-26